US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

(OP:ONNVF)

0.2327 UNCHANGED
Delayed Quote Updated: 3:27 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ONNVF

< Previous 1 2 3 4 Next >
News headline image
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Via ACCESS Newswire
News headline image
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Via ACCESS Newswire
News headline image
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Via ACCESS Newswire
News headline image
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Via ACCESS Newswire
News headline image
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
From OneMedNet Corporation
Via GlobeNewswire
News headline image
Onco-Innovations Announces Closing of Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Amendment to Private Placement Pricing
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Via ACCESS Newswire
News headline image
Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services
Via ACCESS Newswire
News headline image
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
Via ACCESS Newswire
News headline image
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Via ACCESS Newswire
News headline image
Onco-Innovations Attends University of Alberta's 2025 Innovation Awards
Via ACCESS Newswire
News headline image
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Via ACCESS Newswire
News headline image
Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
Via ACCESS Newswire
News headline image
Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
Via ACCESS Newswire
News headline image
Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight
Via ACCESS Newswire
News headline image
Onco-Innovations Appoints Jared Rushton to Board of Directors
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Closing of Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology
Via ACCESS Newswire
News headline image
Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
Via ACCESS Newswire
News headline image
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
Via ACCESS Newswire
News headline image
Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care
Via ACCESS Newswire
News headline image
Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board
Via ACCESS Newswire
News headline image
Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised
Via ACCESS Newswire
News headline image
Onco-Innovations Announces Closing of Private Placement
Via ACCESS Newswire
News headline image
Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement
Via ACCESS Newswire
News headline image
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatments 
From OneMedNet Corporation
Via GlobeNewswire
< Previous 1 2 3 4 Next >